Cardiff Oncology (CRDF) Return on Capital Employed (2012 - 2026)
Cardiff Oncology (CRDF) posted Return on Capital Employed of 105.43% for Q4 2025, down 8.08% sequentially from 97.55% in Q3 2025, and down 3240.0% YoY from 3.36% in Q4 2024.
Cardiff Oncology (CRDF) Return on Capital Employed (2012 - 2026) Analysis & Trends
Cardiff Oncology has reported Return on Capital Employed for 14 years, with the latest figure at 105.43% in Q4 2025.
- Quarterly Return on Capital Employed fell 3240.0% year-over-year to 105.43% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 105.43% (down 3240.0% YoY) and the FY2025 annual result came in at 77.54%, down 1351.0% from the prior year.
- Return on Capital Employed slipped to 105.43% in Q4 2025 per CRDF's latest filing, from 97.55% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 15.98% in Q1 2021 and troughed at 105.43% in Q4 2025.
- A 5-year average of 52.96% and a median of 49.45% in 2023 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2021 and 2024: Return on Capital Employed jumped 20649 bps in 2021, then slumped 3636 bps in 2024.
- Over 5 years, Return on Capital Employed stood at 20.78% in 2021, then plunged by 71 bps to 35.59% in 2022, then slumped by 71 bps to 60.87% in 2023, then slipped by 20 bps to 73.03% in 2024, then slumped by 44 bps to 105.43% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 105.43%, 97.55%, and 85.42% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Cardiff Oncology | 60.21 Mn | 60.21 Mn | - | -113.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -113.87% |
| Dec 31, 2025 | -105.43% |
| Sep 30, 2025 | -97.55% |
| Jun 30, 2025 | -85.42% |
| Mar 31, 2025 | -67.05% |
| Dec 31, 2024 | -73.03% |
| Sep 30, 2024 | -89.34% |
| Jun 30, 2024 | -77.59% |
| Mar 31, 2024 | -67.12% |
| Dec 31, 2023 | -60.87% |
| Sep 30, 2023 | -52.98% |
| Jun 30, 2023 | -45.91% |
| Mar 31, 2023 | -39.60% |
| Dec 31, 2022 | -35.59% |
| Sep 30, 2022 | -33.59% |
| Jun 30, 2022 | -30.01% |
| Mar 31, 2022 | -25.04% |
| Dec 31, 2021 | -20.78% |
| Sep 30, 2021 | -18.79% |
| Jun 30, 2021 | -17.56% |